Florida Cancer Specialists Promotes Jacqueline Ambrose to General Counsel Position

Florida Cancer Specialists Elevates Jacqueline Ambrose to General Counsel

On September 10, 2025, Florida Cancer Specialists & Research Institute, LLC (FCS) made a significant move by promoting Jacqueline Ambrose to the role of General Counsel. This decision underscores the institute’s commitment to enhancing their legal infrastructure, especially in the realm of oncology practice.

In her new role, Ambrose will spearhead the legal strategies that govern the operational framework of the oncology practice at FCS. Her responsibilities will encompass areas such as regulatory compliance, risk management, and corporate governance. With a critical eye on dispute resolutions and complex litigation, she is poised to bolster the institute's legal robustness.

FCS has a rich history spanning over 40 years, standing out as a beacon in the oncology community through its commitment to innovative care and advanced clinical research. By integrating Ambrose into the upper echelon of the executive management team, FCS aims to solidify its operational integrity and enrich its strategic oversight on legal matters, especially as they pertain to medical malpractice.

A Star on the Rise

Jacqueline Ambrose joined FCS in 2021, marking the beginning of her influential journey with the institute. She has previously served as the Associate General Counsel, where she provided valuable guidance on a variety of legal topics including clinical operations, patient privacy, and human resources. Her past contributions have not gone unnoticed.

According to FCS President and Managing Physician, Dr. Lucio N. Gordan, "We are thrilled to welcome Jacqueline into the role of General Counsel. She brings exceptional legal expertise and a deep understanding of our organization's mission and values." This accolade highlights Ambrose’s alignment with FCS’s core principles and her integral role in advancing its legal framework.

Recognition from Leadership

Her unique ability to collaborate effectively across different departments has garnered her trust and respect among senior leadership. Dr. David Wenk, FCS Assistant Managing Physician, remarked, "Jacqueline's collaborative approach, strategic insight, and passion for patient advocacy have earned her recognition as a trusted advisor across departments and among senior leadership."

Moreover, Ryan Ciarrocchi, CEO of FCS, expressed his confidence in Ambrose’s capabilities, stating, "I am confident in Jacqueline - she is well-positioned in her new role to provide exceptional leadership and guidance as we continue to grow and navigate new opportunities for our practice and ultimately our patients."

Focusing on Patient-Centered Care

FCS has made a name for itself in the oncology field not only for its pioneering treatment methods but also for its extensive clinical trials. This promotion comes with the understanding that legal oversight must evolve alongside their clinical practices, ensuring patients receive optimal care in a compliant and risk-managed environment. Indeed, a large percentage of FDA-approved drugs for cancer treatment were first available through FCS's clinical trials, which positions the institute as a leader in research and development in private oncology practices.

As FCS continues to embrace innovation and tackle new challenges in the field of cancer treatment, Jacqueline Ambrose’s role as General Counsel will be pivotal. Her leadership will not only enrich the legal landscape of FCS but also enhance the overall patient experience, assuring that their rights and needs are prioritized.

In conclusion, the appointment of Jacqueline Ambrose represents a significant advancement for the Florida Cancer Specialists & Research Institute. With her extensive legal acumen and dedication to patient advocacy, Ambrose is set to navigate the complexities of oncology law while supporting the institute’s ongoing mission to provide outstanding cancer care.

For more information on Florida Cancer Specialists & Research Institute and their clinical trials, visit FLCancer.com.